1451 related articles for article (PubMed ID: 22610119)
1. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.
Barbieri CE; Baca SC; Lawrence MS; Demichelis F; Blattner M; Theurillat JP; White TA; Stojanov P; Van Allen E; Stransky N; Nickerson E; Chae SS; Boysen G; Auclair D; Onofrio RC; Park K; Kitabayashi N; MacDonald TY; Sheikh K; Vuong T; Guiducci C; Cibulskis K; Sivachenko A; Carter SL; Saksena G; Voet D; Hussain WM; Ramos AH; Winckler W; Redman MC; Ardlie K; Tewari AK; Mosquera JM; Rupp N; Wild PJ; Moch H; Morrissey C; Nelson PS; Kantoff PW; Gabriel SB; Golub TR; Meyerson M; Lander ES; Getz G; Rubin MA; Garraway LA
Nat Genet; 2012 May; 44(6):685-9. PubMed ID: 22610119
[TBL] [Abstract][Full Text] [Related]
2. SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
Hernández-Llodrà S; Segalés L; Safont A; Juanpere N; Lorenzo M; Fumadó L; Rodríguez-Vida A; Cecchini L; Bellmunt J; Lloreta-Trull J
Prostate; 2019 Jul; 79(10):1156-1165. PubMed ID: 31090082
[TBL] [Abstract][Full Text] [Related]
3. The mutational landscape of lethal castration-resistant prostate cancer.
Grasso CS; Wu YM; Robinson DR; Cao X; Dhanasekaran SM; Khan AP; Quist MJ; Jing X; Lonigro RJ; Brenner JC; Asangani IA; Ateeq B; Chun SY; Siddiqui J; Sam L; Anstett M; Mehra R; Prensner JR; Palanisamy N; Ryslik GA; Vandin F; Raphael BJ; Kunju LP; Rhodes DR; Pienta KJ; Chinnaiyan AM; Tomlins SA
Nature; 2012 Jul; 487(7406):239-43. PubMed ID: 22722839
[TBL] [Abstract][Full Text] [Related]
4. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM
Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372
[TBL] [Abstract][Full Text] [Related]
5. Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients.
Stoehr R; Taubert H; Gaisa NT; Smeets D; Kneitz B; Giedl J; Ruemmele P; Wieland WF; Rau TT; Hartmann A
J Pathol; 2013 Aug; 230(4):453-6. PubMed ID: 23661306
[TBL] [Abstract][Full Text] [Related]
6. Traversing the genomic landscape of prostate cancer from diagnosis to death.
Hieronymus H; Sawyers CL
Nat Genet; 2012 May; 44(6):613-4. PubMed ID: 22641202
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.
Jin X; Wang J; Gao K; Zhang P; Yao L; Tang Y; Tang L; Ma J; Xiao J; Zhang E; Zhu J; Zhang B; Zhao SM; Li Y; Ren S; Huang H; Yu L; Wang C
PLoS Genet; 2017 Apr; 13(4):e1006748. PubMed ID: 28448495
[TBL] [Abstract][Full Text] [Related]
8. SPOP mutations in prostate cancer across demographically diverse patient cohorts.
Blattner M; Lee DJ; O'Reilly C; Park K; MacDonald TY; Khani F; Turner KR; Chiu YL; Wild PJ; Dolgalev I; Heguy A; Sboner A; Ramazangolu S; Hieronymus H; Sawyers C; Tewari AK; Moch H; Yoon GS; Known YC; Andrén O; Fall K; Demichelis F; Mosquera JM; Robinson BD; Barbieri CE; Rubin MA
Neoplasia; 2014 Jan; 16(1):14-20. PubMed ID: 24563616
[TBL] [Abstract][Full Text] [Related]
9. The Genomics of Prostate Cancer: emerging understanding with technologic advances.
Rubin MA; Demichelis F
Mod Pathol; 2018 Jan; 31(S1):S1-11. PubMed ID: 29297493
[TBL] [Abstract][Full Text] [Related]
10. Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.
Kämpjärvi K; Kim NH; Keskitalo S; Clark AD; von Nandelstadh P; Turunen M; Heikkinen T; Park MJ; Mäkinen N; Kivinummi K; Lintula S; Hotakainen K; Nevanlinna H; Hokland P; Böhling T; Bützow R; Böhm J; Mecklin JP; Järvinen H; Kontro M; Visakorpi T; Taipale J; Varjosalo M; Boyer TG; Vahteristo P
Prostate; 2016 Jan; 76(1):22-31. PubMed ID: 26383637
[TBL] [Abstract][Full Text] [Related]
11. Clinical and genomic features of SPOP-mutant prostate cancer.
Nakazawa M; Fang M; H Marshall C; Lotan TL; Isaacsson Velho P; Antonarakis ES
Prostate; 2022 Feb; 82(2):260-268. PubMed ID: 34783071
[TBL] [Abstract][Full Text] [Related]
12. SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.
Blattner M; Liu D; Robinson BD; Huang D; Poliakov A; Gao D; Nataraj S; Deonarine LD; Augello MA; Sailer V; Ponnala L; Ittmann M; Chinnaiyan AM; Sboner A; Chen Y; Rubin MA; Barbieri CE
Cancer Cell; 2017 Mar; 31(3):436-451. PubMed ID: 28292441
[TBL] [Abstract][Full Text] [Related]
13. Opposing Roles of
Cavalcante L; Deshmukh SK; Ribeiro JR; Carneiro BA; Dizon DS; Angara K; Mattox T; Wu S; Xiu J; Walker P; Oberley M; Nabhan C; Huang H; Antonarakis ES
JCO Precis Oncol; 2023 Sep; 7():e2300088. PubMed ID: 37677121
[TBL] [Abstract][Full Text] [Related]
14. Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer.
Zhou S; Hawley JR; Soares F; Grillo G; Teng M; Madani Tonekaboni SA; Hua JT; Kron KJ; Mazrooei P; Ahmed M; Arlidge C; Yun HY; Livingstone J; Huang V; Yamaguchi TN; Espiritu SMG; Zhu Y; Severson TM; Murison A; Cameron S; Zwart W; van der Kwast T; Pugh TJ; Fraser M; Boutros PC; Bristow RG; He HH; Lupien M
Nat Commun; 2020 Jan; 11(1):441. PubMed ID: 31974375
[TBL] [Abstract][Full Text] [Related]
15. Pioneer of prostate cancer: past, present and the future of FOXA1.
Teng M; Zhou S; Cai C; Lupien M; He HH
Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061
[TBL] [Abstract][Full Text] [Related]
16. Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas.
McGuire MM; Yatsenko A; Hoffner L; Jones M; Surti U; Rajkovic A
PLoS One; 2012; 7(3):e33251. PubMed ID: 22428002
[TBL] [Abstract][Full Text] [Related]
17. Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants.
Zhang P; Gao K; Tang Y; Jin X; An J; Yu H; Wang H; Zhang Y; Wang D; Huang H; Yu L; Wang C
Hum Mutat; 2014 Sep; 35(9):1142-51. PubMed ID: 24990631
[TBL] [Abstract][Full Text] [Related]
18. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.
Mäkinen N; Vahteristo P; Bützow R; Sjöberg J; Aaltonen LA
Int J Cancer; 2014 Feb; 134(4):1008-12. PubMed ID: 23913526
[TBL] [Abstract][Full Text] [Related]
19. Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.
Tan PY; Chang CW; Chng KR; Wansa KD; Sung WK; Cheung E
Mol Cell Biol; 2012 Jan; 32(2):399-414. PubMed ID: 22083957
[TBL] [Abstract][Full Text] [Related]
20. CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
Zhu Y; Wen J; Huang G; Mittlesteadt J; Wen X; Lu X
Prostate; 2021 Jan; 81(1):81-88. PubMed ID: 33022763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
